Likewise, MG patients have documented dysregulation in cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression, IL-2 sensitivity, and the levels of transforming growth factor beta (TGF-β) gene expression [25, 62, 63]. The gene discussed is CTLA4; the disease is myasthenia gravis.